Below is a roundup of payer-centric news headlines you may have missed during the month of January 2025. | You may have ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...
Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...
WISH-TV on MSN5h
Taco Bell reupping its value menu gameTaco Bell is re-upping its value menu game with the introduction of $5, $7 and $9 luxe cravings boxes, while TikTok is ...
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...
Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...
El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...
Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback